Skip to main content

Table 1 Comparison of control and intervention clinic characteristics during the baseline and evaluation periods

From: A pragmatic randomized trial of a primary care antimicrobial stewardship intervention in Ontario, Canada

Characteristic

Baseline Period (January-February 2018)

Evaluation Period (January-May 2019)

Control

Intervention

p-value

Control

Intervention

p-value

Clinicians

19

31

 

20

33d

 

Total visitsa

634

328

 

943

739

 

After hours visits

15 (2.4%)

47 (14.3%)

<0.001

36 (3.8%)

243 (32.9%)

<0.001

Visits involving residents

102 (16.1%)

56 (17.1%)

0.765

68 (7.2%)

123 (16.6%)

<0.001

Age (mean years, SD)

47.1 (16.8)

51.9 (17.6)

<0.001

47.1 (17.5)

53.4 (19.1)

<0.001

Visits by Females

446 (70.3%)

255 (77.7%)

0.018

666 (70.6%)

568 (76.9%)

0.005

Visits with an Antibiotic allergy

History

111 (17.5%)

95 (29.0%)

<0.001

152 (16.1%)

177 (24.0%)

<0.001

Characteristic

Baseline Period (January-February 2018)

Intervention Period (January-May 2019)

 

Control

Intervention

p-value

Control

Intervention

p-value

Visits by Condition

      

URIb

245 (38.6%)

92 (28.0%)

 

287 (30.4%)

185 (25.0%)

 

Acute sinusitis

91 (14.4%)

69 (21.0%)

 

140 (14.8%)

133 (18.0%)

 

Sore throat

60 (9.5%)

27 (8.2%)

 

91 (9.7%)

81 (11.0%)

 

Acute bronchitis

67 (10.6%)

36 (11.0%)

 

126 (13.4%)

49 (6.6%)

 

Acute cystitis

50 (7.9%)

43 (13.1%)

 

119 (12.6%)

161 (21.8%)

 

Pneumonia

45 (7.1%)

34 (10.4%)

 

69 (7.3%)

66 (8.9%)

 

Influenza

46 (7.3%)

22 (6.7%)

 

47 (5.0%)

15 (2.0%)

 

Otherc

30 (4.7%)

5 (1.5%)

<0.001

64 (6.8%)

49 (6.6%)

<0.001

Crude Prescribing Rate

218 (34.4%)

126 (38.4%)

 

373 (39.6%)

349 (47.2%)

 
  1. a some patients may have had more than 1 visit bURI –upper respiratory tract infection; c Other includes cough (ICD9 786), other urinary conditions (599); d34 providers completed the education but 1 had no visit data